Skip to main content
. 2020 May 28;7:215. doi: 10.3389/fmed.2020.00215

Figure 3.

Figure 3

T1 maps and 3D volumetric images of the liver parenchyma for patient with NLF (A–C) and ALF (D,E). (A–C) The T1-mapping before (A) and 20 min after the administration of Gd-EOB-DTPA (B) and 3D volumetric image (C) in a 47-year-old man with NLF (T1-pre = 694.01 ms, T1-post = 158.08 ms, RLV = 1344.93 mL, ΔT1 = 535.96 ms, ΔT1% = 0.77, volume-assisted ΔT1 = 720828.7 ms.mL, volume-assisted ΔT1% = 1038.60 mL, ICG R-15 = 3.5%). (D,E) The T1-mapping before (D) and 20 min after the administration of Gd-EOB-DTPA (E) and 3D volumetric image (F) in a 55-year-old man with ALF (T1-pre = 668.68 ms, T1-post = 328.67 ms, RLV = 915.30 mL, ΔT1 = 340.01 ms, ΔT1% = 0.51, volume-assisted ΔT1 = 311211.2 ms.mL, volume-assisted ΔT1% = 465.41 mL, ICG R-15 = 15.3%). T1-pre, T1 relaxation time before Gd-EOB-DTPA injection; T1-post, T1 relaxation time 20 min after Gd-EOB-DTPA injection; RLV, residual liver volume; ΔT1, absolute reduction of T1 relaxation time; ΔT1%, reduction rate of T1 relaxation time; volume-assisted ΔT1, ΔT1*RLV; volume-assisted ΔT1%, ΔT1%*RLV; NLF, normal liver function; ALF, abnormal liver function.